Anal Cancer
Circulating Tumor DNA for MRD Detection and Molecular Profiling in HPV-Driven Malignancy
Clinical Overview
Anal squamous cell carcinoma is a rare malignancy accounting for approximately 9,000 new cases annually in the United States. Like cervical cancer, anal cancer is predominantly driven by persistent human papillomavirus (HPV) infection, with HPV-16 being the most common oncogenic subtype. Standard treatment for locally advanced disease consists of definitive chemoradiation, which achieves cure in 70-80% of patients. However, 20-30% experience treatment failure or subsequent relapse, and therapeutic options for metastatic disease have historically been limited to cytotoxic chemotherapy with modest response rates.
Clinical Impact: Circulating tumor DNA testing in anal cancer demonstrates strong prognostic value for identifying treatment failures after chemoradiation, with hazard ratios among the highest observed in solid tumor oncology. HPV DNA detection serves as a tumor-specific marker, enabling sensitive monitoring for residual disease and recurrence. Recent immunotherapy advances provide effective treatment options for advanced disease, creating opportunities to intervene earlier when ctDNA identifies high-risk patients.
Understanding ctDNA Testing Methodology
Clinical Decision Points for Anal Cancer
When to Use Each Approach
| Clinical Scenario | Recommended Approach | Rationale |
|---|---|---|
| Post-chemoradiation MRD detection | Tumor-informed | Maximum sensitivity needed; baseline profiling from diagnostic biopsy |
| Surveillance after complete response | Tumor-informed | Early relapse detection requires high sensitivity |
| Advanced/metastatic disease genotyping | Either approach | Actionable mutations detectable with or without baseline |
| HPV genotyping | Either approach | HPV-16 most common; detection possible with both methods |
LIQOMICS Testing Solutions for Anal Cancer
CancerVista offers tumor-informed ctDNA testing for anal cancer enabling MRD detection after chemoradiation and recurrence surveillance.
Key Features:
- Baseline profiling from tissue biopsy or plasma sample
- Ultra-high sensitivity for MRD detection
- Tracks patient-specific mutations for specific and precise MRD quantification
- Enables ctDNA-guided therapy decisions
- Allows early relapse detection during surveillance
MRD Detection: Strong Prognostic Value
Post-Treatment ctDNA Assessment
Evaluation of ctDNA after systemic chemotherapy for advanced anal cancer has demonstrated strong prognostic associations. Post-treatment ctDNA detection identifies patients at substantially elevated risk of disease progression. Note: the primary Epitopes-HPV02 data is from the advanced/metastatic setting; ctDNA MRD data after curative-intent chemoradiation for locally advanced disease remains more limited.
Epitopes-HPV02 Trial: Post-Chemotherapy Prognostic Data
Study Design: Prospective evaluation of HPV ctDNA in patients with advanced (metastatic or unresectable locally recurrent) anal squamous cell carcinoma treated with first-line chemotherapy (docetaxel, cisplatin, and 5-fluorouracil). HPV16 ctDNA was quantified by droplet digital PCR at baseline and after chemotherapy completion (n=57 patients; 36 evaluable post-chemotherapy).
Clinical Outcomes:
- Baseline Detection Rate: 91.1% (52/57 patients)
- Hazard Ratio for Progression: 5.5 (p<0.001) for residual HPV ctDNA after chemotherapy completion
- Interpretation: Patients with detectable post-chemotherapy ctDNA have approximately 5.5-fold higher risk of disease progression
- Clinical Significance: Post-chemotherapy ctDNA positivity identifies patients at high risk of progression
- Testing Method: HPV16 ctDNA detection by droplet digital PCR
Baseline Detection Rates
HPV ctDNA Detection at Diagnosis:
- Detection Rate: 64-91% depending on disease stage and detection method (higher in advanced disease and stage III)
- HPV-16 Prevalence: Most common oncogenic subtype
- Factors Affecting Detection: Disease burden, tumor location, HPV viral load
- Consideration: Detection rates vary by stage; stage II locally advanced disease may have lower detection than advanced/metastatic disease
Persistent ctDNA After Chemoradiation
Clinical Implications of Persistent HPV ctDNA:
- Predictive Value: Persistent HPV ctDNA after chemoradiation predicts recurrence
- Risk Stratification: Identifies high-risk patients who may benefit from additional interventions
- Negative Predictive Value: ctDNA clearance associated with favorable outcomes
- Clinical Action: ctDNA-positive patients may warrant closer surveillance or clinical trial enrollment
Time-Dependent HPV ctDNA Assessment (Wo et al. 2025)
Prospective Study in Localized Anal Cancer After Chemoradiation:
- Key Finding: Timing of ctDNA assessment is critical -- HPV ctDNA detected at 3 or more months after chemoradiation (not at treatment completion) is prognostic for recurrence
- Recurrence Rate: 80% in HPV ctDNA-positive vs 2% in HPV ctDNA-negative patients at 3 or more months post-chemoradiation
- Hazard Ratio: 39.2 for recurrence-free survival in HPV ctDNA-positive patients
- Clinical Implication: End-of-treatment ctDNA assessment may be too early; 3-month post-treatment timepoint is more informative
- Future Direction: A clinical trial incorporating HPV ctDNA as an integral biomarker for immunotherapy escalation (atezolizumab + tiragolumab) in ctDNA-positive patients is forthcoming
Reference: Wo JY et al. Clin Cancer Res 2025;31(12):2399-2408
Clinical Application: Two key datasets inform ctDNA utility in anal cancer: (1) the Epitopes-HPV02 trial demonstrated HR 5.5 for progression with post-chemotherapy ctDNA positivity in advanced disease, and (2) the Wo et al. 2025 prospective study showed that HPV ctDNA detected at 3 or more months after chemoradiation for localized disease is highly prognostic (HR 39.2). Critically, end-of-treatment assessment may be uninformative -- the 3-month timepoint appears optimal. ctDNA-positive patients may warrant closer surveillance or clinical trial enrollment.
Reference: Bernard-Tessier A et al. Clin Cancer Res 2019;25(7):2109-2115
Comprehensive Molecular Profiling
Beyond MRD detection, molecular profiling in anal cancer identifies targetable mutations and guides treatment selection, particularly in advanced or recurrent disease.
HPV Status and Genotyping
Clinical Context:
- HPV-Positive Rate: Approximately 90% of anal squamous cell carcinomas
- Predominant Types: HPV-16 most common, followed by HPV-18
- Oncogenic Mechanism: HPV E6 and E7 oncoproteins inactivate p53 and pRB tumor suppressors
- ctDNA Utility: HPV DNA fragments detectable in plasma serve as tumor-specific markers
- Monitoring Application: HPV ctDNA used for treatment response assessment and surveillance
PIK3CA Mutations - Emerging Therapeutic Target
Clinical Relevance:
- Frequency: 20-30% of anal cancers
- Function: PI3K pathway activation drives cell growth and survival
- Therapeutic Development: Alpelisib (PI3K-alpha inhibitor) under investigation in clinical trials
- Co-occurrence: Often found alongside HPV infection
- Detection: Identifiable through ctDNA or tissue-based next-generation sequencing
- Clinical Trial Consideration: Patients with PIK3CA mutations may be eligible for PI3K inhibitor trials
Mismatch Repair Deficiency (MMR-deficient/MSI-H) - Rare but Actionable
Immunotherapy Applications:
- Prevalence: Rare in anal cancer (estimated <5%)
- Treatment Option: Pembrolizumab approved for MMR-deficient/MSI-H tumors across cancer types
- Clinical Outcomes: High response rates to immune checkpoint inhibitors
- Detection Method: Tissue-based immunohistochemistry or molecular testing; ctDNA panels can detect MSI-H status
- Testing Recommendation: Consider in refractory disease or unusual clinical presentations
PD-L1 Expression and Immune Checkpoint Inhibitors
Clinical Context for Immunotherapy:
- Nivolumab (NCI9673 Trial):
- Objective Response Rate: 24% in previously treated metastatic disease
- Duration of Response: Median >12 months in responders
- Disease Control Rate: Approximately 50%
- Current Use: Option for second-line or later treatment
- Pembrolizumab:
- Objective Response Rate: 17% in recurrent/metastatic disease (KEYNOTE-028)
- Patient Population: Refractory disease after prior therapy
- Current Use: Option when other therapies are exhausted
- PD-L1 Testing: Expression levels may inform treatment selection, though not mandatory for approval
- Clinical Consideration: Immunotherapy represents valuable option in disease with historically limited treatment choices
TTMV-HPV DNA: Next-Generation Surveillance
Tumor Tissue Modified Viral HPV DNA (TTMV-HPV DNA):
- Approach: NGS-based detection of tumor-modified HPV DNA fragments in blood
- Advantage: Detects multiple HPV types (including uncommon variants), not limited to HPV-16
- Clinical evidence: Retrospective case series (2020-2024) demonstrates non-invasive detection of MRD and recurrence in anal SCC
- Sensitivity: More sensitive and specific than standard ctDNA approaches for HPV-driven cancers
- Status: Emerging technology; prospective validation ongoing
Systematic Review: ctDNA as Biomarker in Anal Cancer
Systematic Review (Int J Mol Sci 2024):
- Scope: 8 studies, 628 total patients
- Conclusion: ctDNA (primarily HPV-based) shows promise as a predictive biomarker for management and prognosis of anal SCC
- Limitation: Heterogeneous study designs, assay methodologies, and endpoints across studies
Integrated Profiling Strategy: Comprehensive molecular profiling in anal cancer serves dual purposes: (1) HPV DNA detection for sensitive MRD monitoring with strong prognostic value (HR 5.5 in advanced disease, HR 39.2 in localized disease at 3+ months post-chemoradiation), and (2) somatic mutation profiling (PIK3CA, MMR status, PD-L1 expression) for potential clinical trial enrollment or immunotherapy selection. The near-universal HPV positivity (approximately 90%) makes HPV ctDNA an ideal tumor-specific marker for serial monitoring after treatment. Emerging TTMV-HPV DNA technology may further improve detection sensitivity.
Clinical Summary
Anal cancer ctDNA testing demonstrates:
- Strong Prognostic Value: HR 5.5 (p<0.001) for progression in advanced disease (Epitopes-HPV02); HR 39.2 in localized disease at 3+ months post-chemoradiation (Wo et al. 2025)
- Timing Matters: HPV ctDNA at 3+ months post-chemoradiation is prognostic (80% vs 2% recurrence); end-of-treatment assessment may be uninformative
- HPV-Based Monitoring: HPV E6/E7 ctDNA serves as tumor-specific marker in approximately 90% of cases
- Detection Rates: Baseline detection ranges from 64-91% depending on stage and method, with higher rates in advanced disease
- Actionable Mutations: PIK3CA (20-30%) for clinical trials; MMR-deficient (rare) for immunotherapy
- Immunotherapy Options: Nivolumab (24% ORR), pembrolizumab (17% ORR) in refractory disease
- Emerging Evidence: Prospective data now available for localized disease (Wo et al. 2025); interventional trials incorporating ctDNA as integral biomarker are forthcoming
Current Clinical Applications
Appropriate Use Cases:
- Post-treatment risk stratification: Identify high-risk patients (HR 5.5 in advanced disease) for intensified surveillance
- Advanced disease genotyping: PIK3CA mutation detection for clinical trial eligibility
- MMR status determination: Identify rare immunotherapy-responsive cases
- Research and clinical trials: Prospective evaluation of ctDNA-guided interventions
Standard Care Remains Primary Approach:
- Clinical examination, imaging, and SCC antigen continue as standard surveillance modalities
- Clinical exam and digital rectal examination remain essential
- PET-CT for treatment response assessment
- Biopsy confirmation for suspected recurrence
Clinical Implementation: Anal cancer ctDNA testing provides valuable prognostic information (HR 5.5 in the advanced disease setting) but faces challenges including limited prospective validation in the curative-intent setting. Current applications focus on risk stratification and molecular profiling for treatment selection, particularly with emerging immunotherapy options. Standard surveillance with tumor markers and imaging remains the established approach, with ctDNA serving as complementary information in select high-risk cases or research settings. Prospective interventional trials are needed to define optimal ctDNA-guided management strategies.
References
- Bernard-Tessier A et al. Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial. Clin Cancer Res 2019;25(7):2109-2115.
- Morris VK et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446-453.
- Ott PA et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-1041.
- Wo JY et al. Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer. Clin Cancer Res 2025;31(12):2399-2408.
- Lefebvre C et al. Assessing circulating tumour DNA (ctDNA) as a biomarker for anal cancer management: a systematic review. Int J Mol Sci 2024;25(7):4005.
- Cabel L et al. The clinical utility of a next-generation sequencing-based approach to detecting circulating HPV DNA in patients with advanced anal cancer. Cancers 2025;17(2):308.
- Kachuri L et al. Evaluating tumor tissue modified viral (TTMV)-HPV DNA for the early detection of anal squamous cell carcinoma recurrence. Cancers 2025;17(2):174.
Evidence summary current through April 2026 | Version 3.0
This educational resource incorporates the latest clinical trial data for ctDNA testing in anal cancer
Related Cancer Types
Explore ctDNA and liquid biopsy evidence for related cancer types: